Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAscendis Pharma AS

Ascendis Pharma AS

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
261.8 USD 2.52 ( 0.97%)
Last update at 2026-11-12T15:44:00Z
VOLUME
200606
Market Cap
15772.88M
P/E
18.49

Momentum Score

…

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
258.50
Low
269.85
High
52 Week Price Range
186.05
Low
282.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Ascendis Pharma A/S develops long-acting hormone therapies using its TransCon prodrug platform; it commercialized the weekly growth hormone lonapegsomatropin after FDA approval for pediatric growth hormone deficiency and is advancing TransCon candidates in other endocrine and rare-disease indications. Long-term growth drivers include uptake of the weekly GH franchise, potential regulatory approvals and launches of additional TransCon programs, and expansion into specialty markets where less-frequent dosing could support patient adherence and payer interest.
Material risks include clinical and regulatory setbacks for pipeline candidates, challenges in commercial execution and reimbursement versus entrenched competitors, and reliance on continued cash generation or external financing to fund development and commercialization.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
259.28
Dividend Yield
-
Revenue TTM
1047.02M
Revenue Per Share
16.89
Gross Profit TTM
955.89M
Debt / Equity
-5.35
ROE
118.78%
Net Debt
255.64M
ROCE
-56.16%
Diluted EPS TTM
12.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -204.26M -373.24M -474.14M -577.82M -383.94M
Net income -219.03M -378.08M -481.45M -583.19M -383.58M
Selling general administrative 448.04M 284.55M 264.41M 221.23M 160.18M
Gross profit 588.53M 319.38M 222.32M 39.04M 4.25M
Reconciled depreciation 17.70M 17.71M 18.91M 17.96M 15.39M
Ebit -130.89M -307.74M -430.08M -573.67M -439.67M
Ebitda -113.90M -290.02M -411.17M -556.04M -423.67M
Depreciation and amortization 17.00M 17.71M 18.91M 17.63M 16.00M
Operating income -130.89M -278.76M -455.54M -561.81M -451.79M
Other operating expenses 822.60M 642.40M 722.26M 612.99M 459.57M
Interest expense 77.46M 65.50M 44.06M 50.49M 3.91M
Tax provision 15.38M 4.84M 7.30M 5.38M -0.37M
Interest income 15.30M 14.36M 16.86M 7.43M 0.69M
Net interest income -44.88M -51.14M -27.21M -43.06M -3.22M
Income tax expense 14.78M 4.84M 7.30M 5.38M -0.37M
Total revenue 691.71M 363.64M 266.72M 51.17M 7.78M
Total operating expenses 719.42M 598.15M 677.86M 600.85M 456.05M
Cost of revenue 103.18M 44.26M 44.40M 12.14M 3.52M
Total other income expense net -73.37M -94.48M -18.60M -16.00M 67.85M
Net income from continuing ops -228.03M -378.08M -481.45M -583.19M -383.58M
Net income applicable to common shares - - - -583.19M -383.58M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1302.02M 1179.49M 825.59M 1089.74M 1084.92M
Intangible assets 0.21M 0.53M 0.92M 1.33M 1.78M
Other current assets 33.70M 39.43M 38.58M 31.72M 25.23M
Total liab 1464.77M 1285.20M 971.28M 826.39M 201.29M
Total stockholder equity -162.75M -105.71M -145.70M 263.35M 883.63M
Other current liab 487.05M 317.77M 76.19M 44.82M 31.34M
Common stock 8.32M 8.15M 7.75M 7.67M 7.65M
Capital stock 8.32M 8.15M 7.75M 7.67M 7.65M
Retained earnings -2699.24M -2559.70M -2278.97M -1860.49M -1413.86M
Other liab - - - 172.16M 2.96M
Good will 3.49M 3.50M 3.50M 3.50M 3.50M
Other assets - - - 1.92M 1.81M
Cash 615.78M 559.54M 392.16M 444.77M 446.27M
Total current liabilities 1068.94M 907.86M 197.34M 171.27M 100.36M
Current deferred revenue 4.94M 0.94M 1.18M - 2.60M
Net debt 255.64M 297.07M 252.10M 63.61M -341.31M
Short term debt 486.32M 491.54M 25.40M 25.42M 7.00M
Short long term debt 486.53M 491.54M 11.23M 25.42M -
Short long term debt total 871.41M 856.62M 644.26M 508.38M 104.96M
Other stockholder equity 2529.92M 2444.06M 2132.43M 3.45M 203.71M
Property plant equipment - - - 129.09M 126.05M
Total current assets 1108.51M 1060.86M 702.72M 923.47M 805.89M
Long term investments 32.53M 13.57M 5.69M 30.42M 145.91M
Net tangible assets - - - 258.52M 878.36M
Short term investments - 0.00M 7.28M 290.69M 235.80M
Net receivables 157.63M 166.28M 55.77M 25.63M 23.19M
Long term debt 385.25M 365.08M 534.25M 482.96M -
Inventory 301.40M 295.61M 208.93M 130.67M 75.41M
Accounts payable 90.62M 96.39M 94.57M 101.03M 59.42M
Accumulated other comprehensive income -1.75M 1.78M -153.45M 255.67M 875.99M
Non currrent assets other - 2.32M 2.13M 1.92M 1.81M
Non current assets total 193.50M 118.63M 122.87M 166.27M 279.04M
Capital lease obligations - - 98.79M - 104.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 6.88M 279.03M 61.73M -86.34M
Change to liabilities - - - 54.59M 44.39M
Total cashflows from investing activities -8.15M 6.88M - 61.73M -110.58M
Net borrowings -21.96M 122.79M - 496.93M -6.43M
Total cash from financing activities 34.89M 443.93M 134.29M 396.77M 351.39M
Change to operating activities - - - -6.41M -11.24M
Net income -219.03M -378.08M -481.45M -583.19M -383.58M
Change in cash 122.65M 167.38M -52.60M -1.50M -138.25M
Begin period cash flow 493.13M 392.16M 444.77M 446.27M 584.52M
End period cash flow 615.78M 559.54M 392.16M 444.77M 446.27M
Total cash from operating activities 51.77M -306.20M -467.36M -495.70M -417.65M
Issuance of capital stock 0.00M 309.91M 0.00M 0.19M 367.88M
Depreciation 17.00M 17.71M 18.91M 17.96M 15.39M
Other cashflows from investing activities - 0.95M - 9.54M 9.54M
Dividends paid - - - 5.06M 33.14M
Change to inventory -5.69M -86.68M -78.26M -55.27M -75.41M
Change to account receivables 14.97M -118.61M -32.10M -11.32M -6.66M
Sale purchase of stock -16.71M 0.00M -1.81M -105.31M -21.61M
Other cashflows from financing activities -10.95M 11.22M 8.47M 5.15M 44.68M
Change to netincome - - - 88.15M -0.55M
Capital expenditures 8.15M 1.43M 2.44M 14.49M 24.23M
Change in working capital 68.16M -107.16M -99.79M -18.62M -48.91M
Stock based compensation 116.17M 95.51M 66.66M 64.18M 66.83M
Other non cash items 182.44M 60.98M 21.00M 18.60M -67.01M
Free cash flow 43.62M -307.62M -469.80M -510.19M -441.88M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ASND
Ascendis Pharma AS		 2.52
0.97%		 261.80 18.49 23.47 15.06 10.46 14.01 76.94
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Ascendis Pharma AS

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Tuborg Boulevard 12, Hellerup, Denmark, 2900

45 70 22 22 44

https://ascendispharma.com

1189

Name Title Year Born
Mr. Jan Moller Mikkelsen Pres, CEO, Member of Exec. Board & Exec. Director 1960
Mr. Michael Wolff Jensen L.L.M. Sr. VP, Chief Legal Officer & Member of the Exec. Board 1971
Dr. Birgitte Volck M.D., Ph.D. Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs 1962
Mr. Scott T. Smith CFO, Sr. VP & Member of Exec. Board 1974
Ms. Lotte Sonderbjerg Chief Admin. Officer, Sr. VP & Member of the Exec. Board 1961
Mr. Peter Rasmussen VP of Fin. & Principal Accounting Officer 1969
Mr. Timothy J. Lee Sr. Director of Investor Relations NA
Mr. Flemming Steen Jensen Sr. VP of Product Supply & Quality 1961
Dr. Kennett Sprogoe Sr. VP and Head of Innovation & Research 1979
Dr. Jens Sigurd Okkels Ph.D. Sr. VP of Product Devel. 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…